RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 94.0%

Neg 94% Neu 0% Pos 0%

RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.